Welcome to our dedicated page for Pathnet SEC filings (Ticker: PTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palatin Technologies, Inc. (PTNT) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures, giving investors structured access to its capital markets activity, collaborations, and risk reporting. As a Delaware-incorporated biopharmaceutical company and smaller reporting company, Palatin files registration statements, current reports, and other documents that explain how it develops melanocortin receptor–based medicines and finances its operations.
Palatin’s registration statements on Form S-1 and S-1/A describe firm commitment public offerings of common stock, pre-funded warrants, and Series J and Series K common stock purchase warrants. These filings detail offering structures, assumed price ranges, warrant exercise terms, underwriter compensation, and closing conditions, including the requirement that Palatin’s common stock be re-listed on the NYSE American. They also summarize the company’s status as a non-accelerated filer and smaller reporting company under SEC rules.
Current reports on Form 8-K provide timely disclosure of material events. Recent 8-Ks cover the NYSE American’s determination that Palatin’s common stock was no longer suitable for listing due to low selling price, the subsequent suspension of trading and transition to OTC markets, and the implementation of a 1-for-50 reverse stock split. Later 8-Ks explain how a business development collaboration with Boehringer Ingelheim and a public equity offering improved stockholders’ equity, supporting Palatin’s plan to regain compliance with NYSE American continued listing standards and resume trading under the symbol PTN.
Other 8-K filings discuss the underwriting agreement for Palatin’s public offering, the terms of Series J and Series K warrants, and the closing of underwriters’ over-allotment options, including the number of additional shares and warrants sold and the resulting gross proceeds. Filings also reference milestone payments under the Boehringer Ingelheim collaboration, specifying upfront and research milestone amounts and eligibility for further development, regulatory, and commercial milestones plus tiered royalties.
Through Stock Titan, users can view these filings as they are posted to EDGAR and use AI-powered summaries to quickly interpret complex sections. For example, AI analysis can highlight how offering proceeds are intended to support Palatin’s obesity and ocular programs, clarify warrant exercise triggers tied to FDA acceptance of an investigational new drug for an in-house obesity compound, and summarize listing compliance discussions with NYSE American. Investors can also monitor insider-related information where applicable, such as participation of executives and directors in offerings, as disclosed in registration statements.
By reviewing Palatin’s 10-K and 10-Q reports alongside 8-Ks and S-1 filings, readers gain a fuller picture of the company’s financial condition, capital structure, risk factors, and progress in advancing melanocortin receptor–based therapies. The filings page, combined with AI-generated insights, helps users navigate lengthy documents and focus on the sections most relevant to PTNT’s clinical, strategic, and financing developments.
Palatin Technologies executive Stephen T. Wills, who serves as Executive VP and CFO/COO, reported the vesting of performance-based equity awards on December 9, 2025 under the company’s 2011 Stock Incentive Plan. He acquired 95, 330, and 345 restricted share units of common stock at a price of $0 per share as certain performance conditions were certified by the Compensation Committee. These restricted share units each represent the right to receive one share of common stock, with the shares to be issued on or before the 60th day following December 9, 2025.
On the same date, Wills also acquired performance-based stock options to buy Palatin common stock: 142 options with a $362.5 exercise price expiring on June 22, 2032, 518 options with a $109.5 exercise price expiring on June 20, 2033, and 495 options with a $91.5 exercise price expiring on June 4, 2034. Following these transactions, he directly beneficially owned 64,053 shares of common stock and 122,913 derivative securities in the form of stock options.
Palatin Technologies, Inc. director equity grant disclosure: A Palatin Technologies director reported receiving two stock option grants on December 9, 2025 under the company’s 2011 Stock Incentive Plan. Each option is a right to buy 2,400 shares of common stock at an exercise price of $21.38 per share, with both grants expiring on December 9, 2035.
One option grant vests on December 9, 2026, but if the director does not serve through December 31, 2026, it is prorated at 1/12 per month from January 31, 2026. The second option grant vests as to 50% on December 9, 2026 and the remaining 50% on December 9, 2027. Following these grants, the director beneficially owns 5,927 derivative securities in the form of stock options, all held directly.
Palatin Technologies, Inc. reported equity compensation changes for its President and CEO, who is also a director, in a Form 4 insider filing. On December 9, 2025, several performance-based restricted stock unit (RSU) awards granted under the 2011 Stock Incentive Plan partially vested after the Compensation Committee certified that a defined performance objective for the 18 months ending December 31, 2025 was achieved at 100% of the target level.
The vesting resulted in accruals of 110, 380, and 395 common shares at a stated price of $0 per share, bringing the reporting person’s beneficial ownership of common stock to 64,698 shares. The company states these shares have not yet been issued but will be delivered on or before the 60th day following December 9, 2025.
On the same date, three tranches of performance-based stock options also vested in part: 163 options at an exercise price of $362.5, 595 options at $109.5, and 568 options at $91.5, each for common stock, with expirations ranging from June 22, 2032 to June 4, 2034. Following these transactions, the reporting person held 123,939 stock options in total.
Palatin Technologies reported a director equity grant for John K.A. Prendergast. On December 9, 2025, he received 2,600 restricted stock units under the 2011 Stock Incentive Plan, split into two grants of 1,300 units each. One grant vests fully on December 9, 2026, and the other vests 50% on December 9, 2026 and 50% on December 9, 2027, each unit representing one share of common stock at no purchase price.
He was also granted 3,200 stock options at an exercise price of $21.38 per share in two blocks of 1,600 options, both expiring on December 9, 2035. One option grant vests on December 9, 2026 with potential monthly proration if service ends before December 31, 2026, while the other vests 50% on December 9, 2026 and 50% on December 9, 2027. Following these transactions, he beneficially owned 15,102 shares of common stock and 27,281 stock options directly.
Palatin Technologies, Inc. reported equity awards to a director in the form of restricted stock units and stock options under its 2011 Stock Incentive Plan. On December 9, 2025, the director received two grants of 1,000 restricted stock units each, at a price of $0 per share, increasing common stock holdings to 14,081 shares held directly after these awards.
The first restricted stock unit grant vests in full on December 9, 2026. The second vests 50% on December 9, 2026 and 50% on December 9, 2027. On the same date, the director was also granted two stock option awards covering 1,200 shares each at an exercise price of $21.38 per share. One option grant vests on December 9, 2026 with proration if board service ends before December 31, 2026, and the other vests 50% on December 9, 2026 and 50% on December 9, 2027.
Janus Henderson Group plc has disclosed a significant ownership position in Palatin Technologies, Inc. common stock. The filing reports beneficial ownership of 170,097 shares, representing 9.99% of Palatin’s common stock, including certain pre-funded and common stock warrants that are exercisable within 60 days but subject to a 9.99% beneficial ownership cap.
The disclosure notes that, because of this cap, an additional 8,562 pre-funded warrants and 182,000 Series J and 182,000 Series K common warrants are not included in the reported figures. A related reporting person, Janus Henderson Biotech Innovation Master Fund Ltd, is shown as beneficially owning 118,196 shares, or 6.6% of the class, with shared voting and dispositive power. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Palatin.
Palatin Technologies executive Stephen T. Wills, Executive VP and CFO/COO, reported routine share-withholding transactions related to tax obligations. On November 14, 2025, the issuer withheld small amounts of common stock (33, 22, 79 and 95 shares) to cover employee withholding taxes tied to previously vested equity awards. The per-share values used were $8 for three grants and $5.5 for one grant, as determined on the respective vesting dates in June 2025. Following these transactions, Wills directly beneficially owned 32,583 shares of Palatin Technologies common stock. The filing is indicated as a Form 4 for one reporting person and reflects tax-related administrative activity rather than an open-market trade.
Palatin Technologies (PTNT): Logos Global Management and affiliated entities filed a Schedule 13G reporting beneficial ownership of 142,292 shares of Common Stock, representing 9.9% of the class. The reporting persons have 0 sole voting/dispositive power and 142,292 shared voting/dispositive power.
The filing lists Logos Global Management LP, Logos Global Management GP LLC, Logos Opportunities Fund IV LP and GP, Arsani William, and Graham Walmsley as reporting persons. The percentage is calculated based on 140,000 shares and warrants to acquire 224,000 shares, and 1,422,060 shares outstanding following the issuer’s offering on November 6, 2025. They certify the holdings are in the ordinary course and not to influence control.
Palatin Technologies Inc. received a Schedule 13G showing that Point72 entities and Steven A. Cohen reported beneficial ownership of 2,307,000 shares of Common Stock, representing 9.9% of the class as of November 12, 2025. The position includes 2,192,000 shares issuable upon exercise of warrants, with certain warrants subject to a 9.99% blocker that limits exercises that would push ownership above that threshold.
The reporting persons list shared voting and dispositive power over 2,307,000 shares and no sole voting or dispositive power. Point72 Asset Management, L.P. manages the securities held by Point72 Associates, with Point72 Capital Advisors, Inc. as its general partner, and Mr. Cohen controlling both entities. The certification states the securities were not acquired for the purpose of changing or influencing control, consistent with a passive Schedule 13G filing.
Palatin Technologies reported that underwriters exercised their over-allotment option tied to its recent public offering. The underwriters purchased 280,615 common shares at $6.50, plus pre-funded warrants for 84,000 shares at $6.50, and the company issued accompanying Series J warrants to buy up to 364,615 shares at $6.50 and Series K warrants to buy up to 364,615 shares at $8.125. This added approximately $2.37 million in gross proceeds, before fees and expenses.
After giving effect to the over-allotment exercise, total gross proceeds from the offering rose to approximately $18.2 million. Palatin also filed a legal opinion covering the securities and noted a related press release.
FAQ
What is the current stock price of Pathnet (PTNT)?
What is the market cap of Pathnet (PTNT)?
